Register
Close-up of laboratory pipette dispensing liquid into test tubes

INSIGHTS

16 Mar 2026

Inside the High-Tech Rebirth of ADCs

Experts have revealed five pivotal shifts in drug design, moving toward a future of safer, integrated, and AI-driven cancer therapies

Roche logo mounted on wooden interior wall

PARTNERSHIPS

10 Mar 2026

New Roche Deal Targets B7H3 Tumors Worldwide

Roche secures global rights to MediLink’s YL201 ADC, expanding its oncology pipeline and deepening cross-border biotech partnerships

Corporate display featuring Taiho Pharma and Araris branding

INNOVATION

20 Feb 2026

Taiho’s Calculated Gamble on Precision ADCs

Taiho’s Araris deal highlights linker chemistry as a critical edge in building safer, more consistent antibody drug conjugates

FDA Food and Drug Administration document with stethoscope

REGULATORY

12 Feb 2026

A Faster Track for Myeloma Treatments?

Draft guidance elevates MRD and complete response, clearing a faster regulatory path for new multiple myeloma therapies

Solve Therapeutics branding displayed on a Nasdaq digital billboard

INVESTMENT

9 Feb 2026

Can Better ADC Engineering Unlock Solid Tumors?

Solve Therapeutics raises $120M with backing from MSD and others, betting that smarter ADC design can finally unlock solid tumors

Bayer logo on headquarters building linked to AI-driven drug design

TECHNOLOGY

4 Feb 2026

Why Antibody Drug Design Is Becoming an AI Problem

AI is reshaping antibody drug design as pharma turns to early partnerships to cut risk, speed timelines, and stay competitive

topics on the agenda

CLEAR OR CROWDED? FTO STRATEGY FOR NEXT GENERATION ADCS

DAY 1: undefined

09:30 - 09:55

OBTAINING BROAD PATENTS IN BIOTECH

DAY 1: undefined

11:30 - 11:55

ACCELERATING ADC LINKER AND PAYLOAD DESIGN THROUGH INTEGRATED COMPUTATIONAL INTELLIGENCE

DAY 1: undefined

12:00 - 12:25

View more topics

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.